Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL

Related Keywords

France ,Dennis Riedl ,Presenterindy Zhang ,Jennifer Viera ,Michael Rhodin ,Presentertessa Cressey ,International Conference On Antiviral Research ,Enanta Pharmaceuticals Inc ,Nasdaq ,Enanta Pharmaceuticals ,International Conference ,Antiviral Research ,Centre De Congres Lyon ,Lyon Convention Center ,Central European Time ,Suppresses Viral Replication ,Oral Antiviral ,Demonstrates Excellent Penetration ,Viral Rebound ,Cindy Zhang ,Once Daily ,Guy De La Rosa ,Throughput Screen ,Identify Non Nucleoside Small Molecule Inhibitors ,Tessa Cressey ,Menanta ,Pharmaceuticals ,Present ,Data ,Protease ,Inhibitor ,Development ,Mural ,Dance ,Daily ,Treatment ,Covid ,6th ,Nternational ,Conference ,Antiviral ,Research ,